tradingkey.logo
tradingkey.logo
Search

Alnylam Pharmaceuticals Inc

ALNY
Add to Watchlist
278.090USD
-4.630-1.64%
Close 06/18, 16:00ETQuotes delayed by 15 min
37.13BMarket Cap
68.06P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-06-18
Previous score
7.81
Change
0
The current earnings forecast score of Alnylam Pharmaceuticals Inc is 7.81, ranking 92 out of 157 in the Pharmaceuticals industry. The average price target is 500.00, with a high of 580.00 and a low of 236.00.

Analyst Rating

Based on 31 analysts
Buy
Current Rating
445.420
Target Price
+60.17%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Alnylam Pharmaceuticals Inc
ALNY
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

What is Alnylam Pharmaceuticals Inc's expected revenue for the next quarter?

Alnylam Pharmaceuticals Inc's expected revenue is 1.32B.

What is Alnylam Pharmaceuticals Inc's price target?

Analysts forecast that Alnylam Pharmaceuticals Inc's price target is USD 500.00, with the highest forecast at USD 580.00 and the lowest forecast at USD 236.00.

How have Alnylam Pharmaceuticals IncALNY's recent earnings per share performed?

The market expectation was USD 1.55, while Alnylam Pharmaceuticals IncALNY's earnings per share (EPS) for the previous quarter was USD 1.41. EPS for the next quarter is expected at USD 1.59.

What is the analyst rating for Alnylam Pharmaceuticals Inc?

Based on the ratings of Alnylam Pharmaceuticals Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
KeyAI